Results 51 to 60 of about 8,055 (251)

Tirzepatide’s innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health

Frontiers in Pharmacology
Tirzepatide, a novel GLP-1/GIP dual receptor agonist, shows significant advantages in glycemic management and weight control. By summarizing the results of the SURMOUNT and SURPASS clinical trials, we evaluate the efficacy and safety of tirzepatide in ...
Jingqi Yang, Yuncheng Gu, Huaigang Chen, Huaigang Chen, Hong Wang, Lang Hong, Bin Li, Liu Yang   +7 more
doaj   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide

JHEP Reports
Background & Aims: In the SYNERGY-NASH trial for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis, tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors ...
Mark L. Hartman, Rohit Loomba, Eric J. Lawitz, Raj Vuppalanchi, Jérôme Boursier, Elisabetta Bugianesi, Masato Yoneda, Yuanyuan Tang, Bram Brouwers, Mathijs C. Bunck, Axel Haupt, Arun J. Sanyal   +11 more
doaj   +1 more source

Drug-induced liver injury secondary to tirzepatide

Tirzepatide is a dual gastric inhibitory polypeptide and glucagon-like peptide-1 receptor agonist, used for the treatment of type 2 diabetes mellitus and obesity. While gastrointestinal side effects are well described in the literature, hepatotoxicity is
Cao, Chester Yixuan, Haig, Adam, Mikhail-Gouda, Peter, Subhaharan, Deloshaan   +3 more
core   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity

Endocrinology, Diabetes & Metabolism Case Reports
We report three obese patients with type 2 diabetes and alcohol-associated liver disease (ALD), including one patient with alcohol use disorder, who exhibited reduced alcohol intake after the initiation of tirzepatide.
Hiroki Takizawa, Akiko Tsuda, Hidehisa Suriki, Hideki Amagane   +3 more
doaj   +1 more source

Tirzepatide for Obesity Treatment and Diabetes Prevention. [PDF]

BackgroundObesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in ...
Aronne, Louis J, Wharton, Sean, Wilding, John PH, Battula, Ramakrishna, SURMOUNT-1 Investigators, Jouravskaya, Irina, Halpern, Bruno, Perreault, Leigh, Bunck, Mathijs C, Jastreboff, Ania M, Stefanski, Adam, Ahmad, Nadia N, le Roux, Carel W, Zhang, Shuyu   +13 more
core   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras Serrano, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Tirzepatide-related acute liver injury

European Journal of Case Reports in Internal Medicine
Tirzepatide, a modified protein containing 39 amino acids, acts as a dual agonist at the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, showing great promise in weight-loss treatment.
Irrum Abdullah, Husam El-Ghousain, Meshaan Alenezi   +2 more
doaj   +1 more source